Morgan Stanley analyst Michael Ulz downgraded Y-mAbs Therapeutics to Underweight from Equal Weight with a $4 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on YMAB:
- Y-mAbs Therapeutics price target lowered to $20 from $23 at Canaccord
- Y-mAbs Therapeutics downgraded to Market Perform from Outperform at Cowen
- Y-mAbs Therapeutics announces strategic objectives for FY23
- Y-mAbs Therapeutics announces restructuring plan, to reduce workforce by 35%
- Y-mAbs Announces Restructuring Plan and Provides Financial Outlook Following Complete Response Letter from FDA